(Q53501518)

14 May 2018

title

Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. (English)

1 reference

14 May 2018

1 reference

E Jeong

1

1 reference

14 May 2018

K E Lee

2

1 reference

14 May 2018

H Jeong

3

1 reference

14 May 2018

B C Chang

4

1 reference

14 May 2018

H S Gwak

5

1 reference

14 May 2018

publication date

15 July 2014

1 reference

14 May 2018

The Pharmacogenomics Journal

published in

1 reference

14 May 2018

volume

15

1 reference

14 May 2018

issue

1

1 reference

14 May 2018

page(s)

33-37

1 reference

14 May 2018

https://scigraph.springernature.com/pub.10.1038/tpj.2014.36

exact match

0 references

cites work

Lifestyle and diet as risk factors for overanticoagulation

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Combinatorial regulation of tissue specification by GATA and FOG factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Activity and tissue-specific expression of the transcription factor NF-E1 multigene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Regulation of human microsomal epoxide hydrolase gene (EPHX1) expression by the transcription factor GATA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Follicle-stimulating hormone-induced activation of Gata4 contributes in the up-regulation of Cyp19 expression in rat granulosa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

The structure of haplotype blocks in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Anticoagulant therapy in Japanese patients with mechanical mitral valves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2014.36

Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves.

21 January 2018

1 reference

12 December 2020

GATA transcription factors: key regulators of hematopoiesis.

1 reference

12 December 2020

Adequate intensity of warfarin therapy for Korean patients with mechanical cardiac valves.

1 reference

12 December 2020

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

1 reference

12 December 2020

Identifiers

DOI

10.1038/TPJ.2014.36

1 reference

14 May 2018

1 reference

14 May 2018